Annovis Bio Inc. (ANVS)
NYSE: ANVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANVS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $44.12M
- EPS (TTM)
- -$1.55
- Dividend yield
- None
- 52-week range
- 0.62 – 5.50
- Day range
- 0.70 – 0.774
- Volume / Avg
- 1.43M / 1.82M
- Beta
- —
- Shares outstanding
- 62.02M
52-week range
ANVS stock today
On Nov 20, ANVS ended the session at $0.7113, shedding $0.0371 (4.96%), versus the S&P 500's 3.70% decline. At this level, ANVS sits near the bottom of its 52-week range of $0.62 to $5.50: 87.1% below the high, set on Nov 28, 2025 and 14.7% above the low. ANVS is down 79.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 81.2%.
Annovis Bio has posted a net loss over the last twelve months (EPS of -$1.55), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Annovis Bio
Company profileAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Maria L. Maccecchini Ph.D.
- Headquarters
- Malvern, PA
- Employees
- 7
- IPO year
- 2020
- Website
- annovisbio.com
Financial highlights
Full financialsIn fiscal 2025, Annovis Bio generated $0 in revenue, up 0.0% from fiscal 2024. Annovis Bio reported a net loss of $28.9 million, compared with a loss of $24.6 million a year earlier. Diluted earnings per share came in at -$1.40.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Growth | — | — | — | — | — |
| Net income | $-28.85M | $-24.59M | $-56.20M | $-25.33M | $-14.49M |
| EPS (diluted) | $-1.40 | $-2.31 | $-6.23 | $-3.10 | $-1.90 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$10.50+1376.17%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.22 vs $-0.30
- Surprise
- +26.67%
ANVS news
All ANVS news- Annovis Bio To Pool Safety Data From Four Buntanetap Studies Following FDA AgreementNasdaqANVS, UHAL.B
- Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDAGlobeNewswire
- Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD StudyGlobeNewswire
- Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Annovis Closes $21 Million Offering, Funds Operations Through Phase 3 Alzheimer's Readout; Stock UpNasdaqANVS, MOG.A
- Annovis Announces Pricing of $21.0 Million Public OfferingGlobeNewswire
- Annovis Bio, Inc. Reports Preliminary Cash and Cash Equivalents of approximately $2.8 millionNasdaq
- Annovis Bio, Inc. Stockholders Approve Increase in Authorized Shares to 140,000,000Nasdaq
Annovis Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GANXGain Therapeutics Inc. | 0.9994 | -4.82% | $44.50M | vs ANVS |
| QUCYQuantum Cyber N.V. | 0.512 | -7.25% | $44.67M | vs ANVS |
| RLYBRallybio Corporation | 15.47 | -0.32% | $43.32M | vs ANVS |
| SPROSpero Therapeutics Inc. | 0.742 | -10.20% | $43.23M | vs ANVS |
| APLMApollomics Inc. Class A | 15.54 | -6.92% | $45.28M | vs ANVS |
| RNXTRenovoRx Inc. | 0.942 | -10.29% | $45.45M | vs ANVS |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 2.06 | -15.40% | $42.45M | vs ANVS |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs ANVS |
Indexes, lists and sector
Annovis Bio stock FAQ
What is Annovis Bio's stock price today?
ANVS last traded at $0.7113 as of Nov 20, 4:00 PM EST, down 4.96% on the day. Prices are delayed at least 15 minutes.
Who is Annovis Bio's CEO?
Dr. Maria L. Maccecchini Ph.D. is the chief executive officer of Annovis Bio Inc., which has about 7 employees.
What is the ANVS 52-week high?
The 52-week high for ANVS is $5.50 and the 52-week low is $0.62. The stock is currently 87.1% below its high.